Noetik Secures $40M Series A to Advance AI-Driven Cancer Therapies
Slice of Healthcare Team
Sep 03, 2024
Key Highlights
- Noetik closes $40M Series A funding round, led by Polaris Partners.
- Funds to expand Noetik's spatial omics-based cancer atlas and CRISPR Perturb-Map platform.
- Polaris Partner Amy Schulman joins the board, with participation from new and existing investors.
Source: Business Wire
Notable Quotes
“ We are thrilled to have the support of incredible investors who share our vision of combining deep patient data and artificial intelligence to build the future of cancer therapeutics. ”
Ron Alfa, M.D., Ph.D., CEO & Co-Founder at Noetik
“ We are excited to partner with Noetik and support their mission to build a pipeline of potentially transformative cancer programs. ”
Amy Schulman, Managing Partner at Polaris Partners
“ The team’s speed of execution in building one of the most sophisticated AI-enabled oncology discovery engines in less than two years is unprecedented. ”
James Hardiman, General Partner at DCVC
